404 related articles for article (PubMed ID: 25064440)
1. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
2. Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Vadivelan S; Sinha BN; Tajne S; Jagarlapudi SA
Eur J Med Chem; 2009 Jun; 44(6):2361-71. PubMed ID: 18929433
[TBL] [Abstract][Full Text] [Related]
3. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
[TBL] [Abstract][Full Text] [Related]
8. Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.
Dessalew N; Bharatam PV
Bioorg Med Chem; 2007 Jun; 15(11):3728-36. PubMed ID: 17399989
[TBL] [Abstract][Full Text] [Related]
9. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK-3β inhibitors.
Liu X; Yu J; Luo Y; Dong H
Chem Biol Drug Des; 2023 Feb; 101(2):326-339. PubMed ID: 35762873
[TBL] [Abstract][Full Text] [Related]
10. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
11. Identification of small molecules that inhibit GSK-3beta through virtual screening.
Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L
Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522
[TBL] [Abstract][Full Text] [Related]
13. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
[TBL] [Abstract][Full Text] [Related]
15. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
16. In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3β.
Mishra P; Kesar S; Paliwal SK; Chauhan M; Madan K
Cent Nerv Syst Agents Med Chem; 2018; 18(2):150-158. PubMed ID: 29848281
[TBL] [Abstract][Full Text] [Related]
17. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
[TBL] [Abstract][Full Text] [Related]
18. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
[TBL] [Abstract][Full Text] [Related]
19. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]